Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

Viking Therapeutics涨5.7%，领跑一众减肥药概念股。该公司最新数据显示，（口服类）减肥药片的效果能同礼来制药与礼来制药的注射针剂竞争。

Justin Zelin, an analyst from BTIG, reiterated the Buy rating on Mersana Therapeutics (MRSN – Research Report). The associated price ...

In a report released today, Joon Lee from Truist Financial assigned a Buy rating to Voyager Therapeutics (VYGR – Research Report). The ...

On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $60.6 which represents a decrease of $-2.37 or -3.76% from the prior close of $62.97. The stock opened at $62.46 and ...

So far this year, Eli Lilly (NYSE: LLY) has been on an absolute tear and is swiftly becoming the world's most prolific ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

ULTY offers a 101% distribution yield but has only delivered 2.4% total performance since inception. Read why ULTY ETF's ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

Research results featured heavily in the news last week, first with Viking Therapeutics releasing promising early-stage data ...

A small player like Viking may also win by attracting a partner or even a company that will offer to acquire the biotech.